OR WAIT null SECS
© 2022 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending May 14, 2021.
In today’s episode of Overdrive by Rheumatology Network, we sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”
Click the image to view the story.
Bryant England, MD, PhD, discusses his study, "Risk of COVID‐19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At‐Risk Individuals." Investigators found that patients with rheumatoid arthritis (RA) are not only at a higher risk for contracting COVID-19, they are more likely to have severe outcomes, such as hospitalization and death, when compared with the general population.
Click the image to view the story.
"Our results suggest that there are likely to be certain treatments that will confer preferential response in psoriatic arthritis (PsA), including tumor necrosis factor (TNF) inhibitors and IL-17 medications, compared to other options," stated Jeffrey Curtis, MD.
Click the image to view the story.
Caregivers are a rheumatologist's most important allies. Learn the warning signs of caregiver burnout and how to combat the symptoms. Remember: their health is prerequisite to patient care.
Click the image to view the story.
Recent analysis indicated that a rheumatoid arthritis (RA) diagnosis pervaded every facet of a patient’s perception of physical activity (PA), both as motivators and as hinderances. These results may be helpful in ultimately creating a PA strategy that can support each individual and improve clinical practice.
Click the image to view the story.